6 mg/kg/dose IV every 24 hours for 2 to 6 weeks is the FDA-approved dosage for right-sided S. aureus endocarditis. Guidelines suggest doses of 8 to 10 mg/kg/dose IV every 24 hours for MRSA endocarditis and 10 to 12 mg/kg/dose IV every 24 hours for multi-drug resistant enterococcal endocarditis as part of combination therapy. Daptomycin is also an alternative option in patients with MSSA left-sided endocarditis. Treat native-valve S. aureus endocarditis for 6 weeks and multi-drug resistant enterococcal endocarditis for more than 6 weeks. Studies have demonstrated the safety of doses of at least 8 mg/kg/dose IV every 24 hours. Limited safety data are available for use beyond 28 days.
Pravachol significantly reduced the rate of first coronary events (either CHD death or nonfatal MI) by 31% (248 events in the placebo group [CHD death=44, nonfatal MI=204] versus 174 events in the Pravachol group [CHD death=31, nonfatal MI=143], p= [see figure below]). The risk reduction with Pravachol was similar and significant throughout the entire range of baseline LDL cholesterol levels. This reduction was also similar and significant across the age range studied with a 40% risk reduction for patients younger than 55 years and a 27% risk reduction for patients 55 years and older. The Pravastatin Primary Prevention Study included only men, and therefore it is not clear to what extent these data can be extrapolated to a similar population of female patients.
Body as a Whole: chest pain; abdominal pain; edema; chills; malaise Cardiovascular: atrial fibrillation; tachycardia; palpitations, and other cardiac arrhythmias; postural hypotension, orthostasis; hypotension; syncope Eye: toxic amblyopia; cystoid macular edema; ophthalmoplegia; eye irritation, blurred vision, progression of cataracts Gastrointestinal: activation of peptic ulcers and peptic ulceration; dyspepsia; vomiting; anorexia; constipation; flatulence, pancreatitis; hepatitis; fatty change in liver; jaundice; and rarely, cirrhosis, fulminant hepatic necrosis, and hepatoma, eructation, fatal and non-fatal hepatic failure Metabolic: gout, decreased glucose tolerance Musculoskeletal: muscle cramps; myopathy; rhabdomyolysis; arthralgia, myalgia Nervous: dizziness; insomnia; dry mouth; paresthesia; anxiety; tremor; vertigo; peripheral neuropathy; psychic disturbances; dysfunction of certain cranial nerves, nervousness, burning sensation/skin burning sensation, peripheral nerve palsy Psychiatric depression Skin: hyper-pigmentation; acanthosis nigricans; urticaria; alopecia; dry